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Abstract. Clinical  decision  support  systems  have  been  developed  to  help 
physicians to take clinical guidelines into account during consultations. The ASTI 
critiquing module is one such systems; it provides the physician with automatic 
criticisms when a drug prescription does not follow the guidelines. It was initially 
developed for  hypertension and type  2 diabetes,  but  is  designed to  be  generic 
enough for application to all chronic diseases.
We present here the results of usability and satisfaction evaluations for the ASTI 
critiquing  module,  obtained  with  GPs  for  a  newly  implemented  guideline 
concerning dyslipaemia,  and  we discuss the lessons learnt  and the  difficulties 
encountered when building a generic DSS for critiquing physicians' prescriptions.
Keywords. Evidence-based  guidelines,  Decision  support,  Evaluation, 
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Introduction
Clinical  guidelines  (CG)  provide  physicians  with  recommendations,  but  paper 
guidelines are difficult to use effectively during medical consultations1. This difficulty 
has led to the development of decision support systems (DSS) based on CG2. The ASTI 
project aims to develop a DSS to help physicians to take into account the treatment  
recommendations expressed in CG for chronic diseases3.  ASTI includes a critiquing 
module that is automatically activated when the physician writes a drug prescription, 
and which issues an alert if the prescription does not follow the CG. The critiquing 
module was initially developed for hypertension and type 2 diabetes. However, unlike 
many DSS which focus on a single CG, ASTI is designed to be generic enough to cover 
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all chronic diseases. To ensure the generic aspect of the system, a new CG concerning 
dyslipaemia4 was implemented, and evaluated in the current study.
The  critiquing  module5 and  the  validation  of  its  knowledge  bases6 have  been 
presented elsewhere. The CG recommendations are modeled in the critiquing module’s 
knowledge base, and are then automatically translated into critiquing rules of the form 
“if physician prescribed treatment X to a patient with clinical condition P, then show 
criticism C”. An inference engine applies these rules, and has been integrated into éO 
généraliste, an electronic patient record (EPR) for general practitioners (GPs). Drug 
prescriptions,  laboratory  test  results  and  some clinical  conditions  are  automatically 
extracted from the EPR and used by the critiquing module. Other clinical conditions 
required by the critiquing module are entered manually by physicians on a special form 
integrated in the EPR and displayed when a patient is included in the ASTI study at the 
beginning of the consultation.
We present here the results of the usability and satisfaction evaluations of the ASTI 
critiquing module for dyslipaemia, and we discuss the lessons learnt and the difficulties 
we encountered in the construction of this generic DSS.
1. Methods
A knowledge base has been designed and tested for the CG relating to dyslipaemia, as 
previously described5,6.  It  includes 28 decision criteria  (patient's  clinical  conditions, 
laboratory test results, etc.), 15 drug treatments and 17 recommendations, resulting in 
73  critiquing  rules.  We  evaluated  the  critiquing  module  for  dyslipaemia  in  the 
laboratory with 33 GPs. The GPs were éO users who volunteered to participate.
Two evaluations were performed with the ASTI critiquing module for dyslipaemia. 
Usability was evaluated using five simulated cases. These cases were derived, by an 
expert, from real cases, and were selected to cover the various aspects of the CG. The  
GPs were first briefly introduced to the use of the ASTI critiquing module. They were 
then asked, for each case, to code the data for the patient into the EPR and to enter two  
prescriptions: the usual prescription the doctor would write and a prescription that he or 
she did not consider to satisfy the CG. For each prescription, the physicians were asked 
to indicate whether they expected an alert, whether an alert was raised, whether the 
alert (or the absence of it) was justified, and whether the explanations and proposals  
accompanying the alert were appropriate. Additional textual comments were possible.
Satisfaction was evaluated just after the GPs had used the system. This evaluation 
was based on seven sentences. For each sentence, the GP had to tick one of four boxes, 
indicating strong agreement with the sentence, weak agreement, weak disagreement or 
strong disagreement. The evaluation was followed by a focus group, during which GPs 
were asked about the system, the way they used it and their feelings about it.
2. Results
The usability evaluation involved 299 prescriptions (less than 2x5x33, because some 
GPs did not reply to all questions, e.g. they rarely tried a second prescription if the first 
one was already criticized), divided as shown in Figure 1. The system's specificity was 
94±1.4% (95% confidence interval) and the sensitivity 84±2.1%. The 136 true positives 
includes  both  prescriptions  criticized  as  expected,  or  unexpectedly  if  the  GP then 
agreed with the criticism; for 114 (84±2.1%) of the true positives, the GP considered 
the system’s explanations and treatment proposals as appropriate. In 80±2.3% of cases, 
the system raised an appropriate criticism or was silent with good reason.
Figure 1. Results of the usability evaluation.
The results of the satisfaction evaluation are shown in Table 1. The physicians 
were  interested  in  receiving  automatic  criticisms  about  their  prescriptions  and  they 
found the ASTI critiquing module easy to use. However, they also felt that the use of 
the module interfered with doctor-patient relations. Further discussions with physicians 
showed that this problem was related to the time required to code the clinical context 
for the patient in the form displayed during the first consultation with the patient.
Table 1. Evaluation of satisfaction, expressed in percent (%)
Question Agreement Disagreement
Strong Weak Weak Strong
I would like to receive automatic criticisms or suggestions 
relating to my prescriptions
39 58 3 0
The ASTI critiquing module is easy to use 3 88 9 0
The response time of the ASTI critiquing module is satisfactory   73 24 3 0
The ASTI critiquing module is ergonomic 18 73 9 0
The ASTI critiquing module can be effectively integrated into 
my daily practice                         
28 66 6 0
The ASTI critiquing module interferes little with my relationship 
with the patient                         
0 27 67 6
Extending the ASTI critiquing module to other guidelines would 
be a major step forward
33 64 0 0
3. Discussion and conclusion
In this study, we evaluated the usability of and satisfaction with the ASTI critiquing 
module  for  dyslipaemia,  a  condition  different  from  the  hypertension  and  type  2 
diabetes  initially  used  for  designing  the  system.  Many other  chronic  diseases  (e.g. 
asthma,  cystic  fibrosis,...)  also  have  complex  drug  treatments  evolving  over  long 
periods of time, the optimal treatment depending on several factors (lab test results, 
clinical  conditions,...).  The system's specificity was high, and the GPs expressed an 
interest in critiquing systems.
Similar evaluation designs, based on simulated cases, have already been used for 
evaluating  DSS7,8.  It  would  be  interesting  to  carry  out  further  evaluations  of  the 
critiquing  system  on  real  practice.  Performing  evaluation  on  voluntary  GPs  is  a 
possible bias since they are usually enthusiastic, but this can hardly be avoided.
The first lesson learnt from this study is that it is possible to design a generic DSS 
supporting several CG for chronic diseases, despite the considerable heterogeneity of 
the various CG, which follow different treatment strategies (e.g. the CG for type 2 
diabetes  follows  a  “waterfall”-like  linear  strategy,  depending  on  the  stage  of  the 
disease,  whereas  the  CG  for  dyslipaemia  follow  a  “star”-like  non-linear  strategy 
depending on the type of dyslipaemia) and are often based on implicit knowledge (e.g. 
the CG does not generally mention that drug doses can be lowered to reduce adverse 
effects).  Currently,  five  CG have been implemented:  hypertension,  type  2 diabetes, 
dyslipaemia, tobacco addiction, atrial fibrillation5. A few other DSS frameworks, such 
as Asbru9 and others10, have achieved a similar level of genericity.
Another lesson is that an automatic DSS, like this critiquing module, requires tight 
integration with the EPR used by the physician. However, as the various EPR include 
essentially the same patient data, it is possible to integrate a DSS into many different 
EPR. Semantic interoperability is easy to achieve, because a DSS usually has a limited 
number of  decision criteria (e.g. 28 for dyslipaemia).  During the ASTI project,  the 
critiquing  module  was  integrated  into  another  EPR,  ALMA Pro,  produced  by  the 
ALMA association. The difficulties encountered during the integration process were 
organizational and financial rather than scientific or technical.
A third lesson is that physicians are interested in receiving automatic criticism on 
their prescriptions. This finding is consistent with other studies showing that physicians 
prefer  automatic  “background” DSS over  “on-demand” DSS11,12.  However,  we also 
learnt  that  displaying  the  CG textual  excerpts  applying  to  the  patient  (as  in  older 
versions of the critiquing module, but not the one used during the evaluation) is not 
sufficient  for  the  critiquing  of  physicians’  prescriptions.  Indeed,  CG  give 
recommendations such as “when the patient has clinical context C, drug W should be 
prescribed”. However, they do not explain to the physician why the drug X, Y or Z he 
prescribed is not appropriate. For a given patient, many prescribing errors are possible 
and  should receive different  criticisms:  e.g. drug X may be contraindicated due to 
another disease that the patient has,  drug Y may be indicated only as a second-line 
treatment, and drug Z may already have been prescribed a year ago without success.
The major difficulty encountered is the coding of the patient's clinical conditions. 
The existing terminologies were developed for the coding of patient data in the EPR, 
but are not always relevant for coding decision criteria from CG. For instance, we were 
unable to code “family antecedent of myocardial infarction in the father before the age 
of 55” and “type 2 diabetes discovered at an advanced stage”. Moreover, physicians do 
not usually code clinical elements in patient records. Instead, they tend to write them in 
free text, which is not usable by DSS as-is. While it might be possible to convince  
some physicians to code the principal diseases and antecedents of the patient, they are  
unlikely to code systematically complex decision criteria, such as those cited above. 
This  problem  has  also  been  encountered  in  the  ASTI  guiding  module13,  and  is 
considered as one of the tenth “DSS grand challenges”14. By contrast, the coding of 
laboratory  results  and  drug  prescriptions is  less  problematic:  test  result  criteria  are 
generally simple in CG, and drug databases can be used for coding drug prescriptions.
Other difficulties relate to the CG themselves: they do not always provide clear 
recommendations, instead sometimes providing only “food for thought”, which is not 
sufficient for critiquing. The various strength levels of recommendations are useful but 
not always mentioned in CG. In some situations, two CG may be contradictory. For 
example, the French CG for hypertension and for dyslipaemia give different formulas 
for determining cardiovascular risk level.  Formalizing CG during their development 
may help to resolve these problems15.
In conclusion, we have shown that the ASTI critiquing module, initially developed 
for hypertension and type 2 diabetes, is generic enough for application to dyslipaemia 
with good results. We have also shown that this module is of interest to physicians. The 
main difficulty is the coding of the patient's clinical conditions, but several approaches 
could be applied to  this  problem. First,  graphical  user  interfaces or  automated text  
processing tools could be designed to help physicians with data entry.  Second,  the 
coding of some clinical conditions could be done after the possible criticism rather than 
before,  the physician explaining the reasons of  his  decision to  the  system. Finally, 
rather than executing the CG entirely, as the critiquing module does, other DSS might 
consist in presenting the CG to the physicians in a more usable form than plain text, 
possibly through graphical approaches.
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